CN113005084A - 一种将体外富集的pbmc扩增活化cd8+t细胞群的方法 - Google Patents
一种将体外富集的pbmc扩增活化cd8+t细胞群的方法 Download PDFInfo
- Publication number
- CN113005084A CN113005084A CN202110287550.6A CN202110287550A CN113005084A CN 113005084 A CN113005084 A CN 113005084A CN 202110287550 A CN202110287550 A CN 202110287550A CN 113005084 A CN113005084 A CN 113005084A
- Authority
- CN
- China
- Prior art keywords
- cells
- concentration
- coated cell
- inoculation bottle
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 97
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 51
- 238000000338 in vitro Methods 0.000 title claims abstract description 25
- 230000003213 activating effect Effects 0.000 title claims description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 95
- 238000011081 inoculation Methods 0.000 claims abstract description 38
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 23
- 239000011886 peripheral blood Substances 0.000 claims abstract description 23
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 18
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims abstract description 15
- 229960003603 decitabine Drugs 0.000 claims abstract description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 15
- 230000003321 amplification Effects 0.000 claims abstract description 14
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 11
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 11
- 238000007664 blowing Methods 0.000 claims abstract description 8
- 239000012679 serum free medium Substances 0.000 claims abstract description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 8
- 238000010009 beating Methods 0.000 claims abstract description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 30
- 239000006228 supernatant Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001917 Ficoll Polymers 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 abstract description 8
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 230000004913 activation Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 4
- 241000239218 Limulus Species 0.000 description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 description 2
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005851 tumor immunogenicity Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960005423 diatrizoate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
细胞表面抗原 | 细胞类型 | 检测值(%) | 标准要求 |
Lym | 淋巴细胞 | 60.2 | ≥50% |
CD3+ | 总T细胞 | 93.0 | ≥80% |
CD3+CD4+ | T辅助/诱导细胞 | 3.58 | <40% |
CD3+CD8+(CD4-) | T抑制/细胞毒细胞 | 89.2 | ≥60% |
CD4+/CD8+ | CD4+与CD8+比值 | 0.04 | <0.5 |
CD56+ | 总NK细胞 | 34.9 | ≥10% |
CD3+CD56+ | NK样T细胞 | 33.3 | 10%~30% |
CD3+/HLA-DR+ | 活化总T细胞 | 88.4 | ≥80% |
CD3+/HLA-DR- | 静止总T细胞 | 4.50 | <20% |
HLA-DR+ | MHC-Ⅱ类分子 | 93.47 | ≥50% |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110287550.6A CN113005084A (zh) | 2021-03-17 | 2021-03-17 | 一种将体外富集的pbmc扩增活化cd8+t细胞群的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110287550.6A CN113005084A (zh) | 2021-03-17 | 2021-03-17 | 一种将体外富集的pbmc扩增活化cd8+t细胞群的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113005084A true CN113005084A (zh) | 2021-06-22 |
Family
ID=76409384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110287550.6A Pending CN113005084A (zh) | 2021-03-17 | 2021-03-17 | 一种将体外富集的pbmc扩增活化cd8+t细胞群的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113005084A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113583955A (zh) * | 2021-08-24 | 2021-11-02 | 羽铂精制生物技术(成都)有限公司 | 一种因子法扩增t细胞的培养基及培养方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890736B1 (en) * | 2002-09-20 | 2005-05-10 | Immunex Corporation | Methods for producing proteins in cultured cells |
WO2013192294A1 (en) * | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
CN105219708A (zh) * | 2015-07-21 | 2016-01-06 | 中山大学 | 免疫细胞培养试剂盒、免疫细胞培养方法和应用 |
CN105349489A (zh) * | 2015-12-07 | 2016-02-24 | 广州赛莱拉干细胞科技股份有限公司 | 一种cik细胞的培养方法 |
CN106244534A (zh) * | 2016-08-15 | 2016-12-21 | 安徽省新安干细胞工程有限公司 | 一种细胞毒型混合杀伤细胞的制备方法 |
US20170107490A1 (en) * | 2014-06-11 | 2017-04-20 | Polybiocept Ab | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
CN106834228A (zh) * | 2017-01-17 | 2017-06-13 | 上海市公共卫生临床中心 | 一种体外扩增cd8+t细胞及其细胞亚群的方法 |
US20210163890A1 (en) * | 2015-12-30 | 2021-06-03 | Celgene Corporation | T lymphocyte production methods and t lymphocytes produced thereby |
CN213951184U (zh) * | 2020-11-25 | 2021-08-13 | 中科德佑(山西)生物科技有限公司 | 一种用于鸡尾酒式分层加入血液混合物的辅助装置 |
-
2021
- 2021-03-17 CN CN202110287550.6A patent/CN113005084A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890736B1 (en) * | 2002-09-20 | 2005-05-10 | Immunex Corporation | Methods for producing proteins in cultured cells |
WO2013192294A1 (en) * | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
US20170107490A1 (en) * | 2014-06-11 | 2017-04-20 | Polybiocept Ab | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
CN105219708A (zh) * | 2015-07-21 | 2016-01-06 | 中山大学 | 免疫细胞培养试剂盒、免疫细胞培养方法和应用 |
CN105349489A (zh) * | 2015-12-07 | 2016-02-24 | 广州赛莱拉干细胞科技股份有限公司 | 一种cik细胞的培养方法 |
US20210163890A1 (en) * | 2015-12-30 | 2021-06-03 | Celgene Corporation | T lymphocyte production methods and t lymphocytes produced thereby |
CN106244534A (zh) * | 2016-08-15 | 2016-12-21 | 安徽省新安干细胞工程有限公司 | 一种细胞毒型混合杀伤细胞的制备方法 |
CN106834228A (zh) * | 2017-01-17 | 2017-06-13 | 上海市公共卫生临床中心 | 一种体外扩增cd8+t细胞及其细胞亚群的方法 |
US20200063103A1 (en) * | 2017-01-17 | 2020-02-27 | Shanghai Innovational Chang'An Biological Technology Co., Ltd. | Method for amplifying cd8+t cells and cell subpopulations thereof in-vitro |
CN213951184U (zh) * | 2020-11-25 | 2021-08-13 | 中科德佑(山西)生物科技有限公司 | 一种用于鸡尾酒式分层加入血液混合物的辅助装置 |
Non-Patent Citations (3)
Title |
---|
PAOLA OLIOSO等: "Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial", 《HEMATOLOGICAL ONCOLOGY》 * |
YAO WANG等: "Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming", 《NATURE COMMUNICATIONS》 * |
胡永仙: "调节性γδT细胞在移植物抗原宿主病中的作用及机制研究", 《中国博士学位论文全文数据库》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113583955A (zh) * | 2021-08-24 | 2021-11-02 | 羽铂精制生物技术(成都)有限公司 | 一种因子法扩增t细胞的培养基及培养方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hamburger et al. | Direct cloning of human ovarian carcinoma cells in agar | |
CN102268405B (zh) | 自体nk细胞体外活化扩增培养的方法及其专用培养基 | |
KR101760764B1 (ko) | Nk세포의 대량 증식을 위한 배양방법 | |
CN102321581B (zh) | 腹水肿瘤细胞致敏dc-cik的制备方法 | |
Wang et al. | Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-α | |
CN113699106A (zh) | 一种细胞因子诱导的杀伤细胞的分离和扩增方法 | |
WO2023216799A1 (zh) | 一种人nkt细胞系及其应用 | |
CN115386550A (zh) | 一种评价免疫细胞抗癌有效性的方法 | |
CN109536444B (zh) | 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法 | |
CN112662631B (zh) | 一种car-t细胞灌流培养方法 | |
CN113005084A (zh) | 一种将体外富集的pbmc扩增活化cd8+t细胞群的方法 | |
CN111548994B (zh) | 一种细胞培养基及其培养nk细胞的方法 | |
CN112852728A (zh) | 基于外周血的lcl-nk细胞联合培养方法、细胞及产品 | |
CN111172110B (zh) | 一种脐带血cik细胞的培养方法 | |
CN113564115B (zh) | 一种高扩增型dc-cik细胞及其制备和应用 | |
CN113481157B (zh) | 特异性抗病毒过继免疫细胞的优化制备方法 | |
CN111154721B (zh) | Nk细胞扩增方法 | |
US7087431B2 (en) | Ex vivo generation of functional leukemia cells in a three-dimensional bioreactor | |
JP2011512846A5 (zh) | ||
CN109251891B (zh) | 一种cd40联合pd-l1及细胞因子扩增pbmc的方法 | |
CN110564684A (zh) | 一种体外稳定、大量扩增、高细胞毒活性的nk细胞的方法及应用 | |
TWI780516B (zh) | 胞毒t細胞培養方法 | |
WO2024067673A1 (zh) | 肿瘤抗原特异性记忆性cd8 t细胞的鉴定、体外扩增及应用方法 | |
CN116179483B (zh) | 一种体外快速扩增干细胞样记忆性宫颈癌肿瘤浸润淋巴细胞的方法 | |
TWI669400B (zh) | 用於體外擴增自然殺手細胞及自然殺手t細胞之無血清細胞培養液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210719 Address after: 030000 West House of plant 22, small and medium-sized enterprise Industrial Park, No. 36, Jingu Road, Xiaohe Industrial Park, Shanxi transformation and comprehensive reform demonstration zone, Taiyuan City, Shanxi Province Applicant after: Zhongkedeyou (Shanxi) Biotechnology Co.,Ltd. Address before: 030051 No.57, Zhongchuang space, Bo Chuang Weiye company, No.15, science and Technology Street, Taiyuan Xuefu Park, Shanxi comprehensive reform demonstration zone, Taiyuan City, Shanxi Province Applicant before: Shanxi Huaijin Jiye Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210622 |
|
RJ01 | Rejection of invention patent application after publication |